Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

An increased risk of ovarian cancer associated with polymorphism in BRCC5 gene in Caucasian populations

Authors: Hua Liang, Yan Li, Ruo-Yu Luo, Fu-Jin Shen

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

Several reports on the association between the BRCC5 gene polymorphism and ovarian cancer risk have been published recently, but the estimates of the risk vary widely. We thus performed a meta-analysis in an effort to determine the association. To identify the eligible studies, we searched the PubMed, Embase, and CNKI databases, and reviewed all original studies retrieved as well as their citations. The risk of ovarian cancer was estimated using odds ratio (OR) and its 95 % confidence interval (CI). Meta-analysis of seven comparisons revealed an obvious rise in the risk of ovarian cancer under the CC vs. GG contrast model (OR = 1.52, 95 % CI = 1.07–2.16, P OR = 0.020). A similar increase was also indicated in the CC vs. GC + GG model (OR = 2.10, 95 % CI = 1.51–2.93, P OR < 0.001). Our meta-analysis indicates that the BRCC5 polymorphism may be a candidate modifier of ovarian cancer risk in Caucasians.
Literature
1.
2.
Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res. 2003;532(1–2):103–15.PubMedCrossRef
3.
Yamamoto A et al. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet. 1996;251(1):1–12.PubMed
4.
Yuan SS, Chang HL, Lee EY. Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(−/−) and c-Abl(−/−) cells. Mutat Res. 2003;525(1–2):85–92.PubMedCrossRef
5.
Vispe S, Defais M. Mammalian Rad51 protein: a RecA homologue with pleiotropic functions. Biochimie. 1997;79(9–10):587–92.PubMedCrossRef
6.
Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998;23(7):247–51.PubMedCrossRef
7.
8.
Lim DS, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol. 1996;16(12):7133–43.PubMedCentralPubMed
9.
Lambert S, Lopez BS. Inactivation of the RAD51 recombination pathway stimulates UV-induced mutagenesis in mammalian cells. Oncogene. 2002;21(25):4065–9.PubMedCrossRef
10.
Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005;219(2):125–35.PubMedCrossRef
11.
Hasselbach L et al. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol. 2005;26(6):589–98.PubMed
12.
Webb PM et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):319–23.PubMedCrossRef
13.
Auranen A et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer. 2005;117(4):611–8.PubMedCrossRef
14.
Jakubowska A et al. The RAD51 135 G > C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2007;16(2):270–5.PubMedCrossRef
15.
Smolarz B et al. Association between polymorphisms of the DNA repair gene RAD51 and ovarian cancer. Pol J Pathol. 2013;64(4):290–5.PubMedCrossRef
16.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
17.
18.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef
19.
20.
Hernandez JL, Weir BS. A disequilibrium coefficient approach to Hardy-Weinberg testing. Biometrics. 1989;45(1):53–70.PubMedCrossRef
21.
Levy-Lahad E et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A. 2001;98(6):3232–6.PubMedCentralPubMedCrossRef
22.
Vuorela M et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat. 2011;130(3):1003–10.PubMedCrossRef
23.
Nagle CM et al. Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Lett. 2007;251(1):96–104.PubMedCrossRef
24.
Wang WW et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001;10(9):955–60.PubMed
25.
Romanowicz-Makowska H et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33(4):406–10.PubMed
26.
27.
28.
Wang WTM, Doody M, Tarone RE, Struewing JP. A single nucleotide polymorphism in the 5-prime-UTR of RAD51 is associated with the risk of breast cancer among BRCA1/2 mutation carriers [abstract]. Am J Hum Genet. 1999;65:A22.
29.
Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.PubMedCentralPubMedCrossRef
Metadata
Title
An increased risk of ovarian cancer associated with polymorphism in BRCC5 gene in Caucasian populations
Authors
Hua Liang
Yan Li
Ruo-Yu Luo
Fu-Jin Shen
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2135-2

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women

Research Article

Aberrant promoter methylation of p15 INK4b and p16 INK4a genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis

Research Article

E-cadherin gene methylation in lung cancer

Research Article

TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway

Research Article

Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus

Research Article

The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits